BENICIA, Calif., March 5 /PRNewswire/ -- AcroMetrix, a global leader in quality control materials and standards for molecular and serological diagnostics, announced today that it has entered into an agreement with Beckman Coulter Inc. for the development and supply of molecular quality control standards for various molecular targets.
AcroMetrix provides In Vitro Diagnostic manufacturers and clinical laboratories with quality control products for molecular testing of infectious disease, oncology, and genetics. These products provide a means by which to establish and monitor assay performance and estimate accuracy and detect systematic errors in molecular diagnostic assays.
"This agreement demonstrates the importance of quality control and standardization in molecular diagnostic testing. We are excited to be working with Beckman Coulter, a leader in the In Vitro Diagnostic industry," said Michael J. Eck, President and CEO for AcroMetrix.
The agreement includes the initial development and supply of quality control standards for 10 molecular targets that will be used in the development of Beckman Coulter's molecular UniCel DxN instrument. This agreement was made possible through AcroMetrix' Contract Manufacturing department which provides customers with high quality, tailored solutions enabling customers to benefit on the years of experience developed by AcroMetrix in the field of molecular quality control materials.
About AcroMetrix - AcroMetrix, with facilities in Benicia, California and Alkmaar, the Netherlands, provides a comprehensive line of molecular and serological diagnostic quality control products that assist laboratories in meeting current regulations regarding quality. AcroMetrix maintains this leadership role by consistently developing innovative standards, external run controls, and validation kits for molecular and serological testing in clinical diagnostics and blood screening laboratories. For more information on AcroMetrix please visit the company web site at http://www.acrometrix.com.
Copyright©2008 PR Newswire.
All rights reserved